
Middle East and Africa Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Resea
Description
Middle East and Africa Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)
The Middle East & Africa (MEA) cervical cancer diagnostic testing market is expected to grow from US$ 218.90 million in 2021 to US$ 282.38 million by 2028. It is estimated to grow at a CAGR of 3.7% from 2021 to 2028. Healthcare players concentrate on several countries due to the large population suffering from cancer in these countries. Moreover, with rising production costs against their practices, they strive to produce sufficient revenue to entertain their investors. Having a presence in growing countries offers reliable and profitable growth opportunities to the major players to lower their operating costs and expand their geographic reach. Advancements in biotechnology have increased the demand for improved diagnostics based on analytical systems in the healthcare market in several countries; they are also easing the shift toward point-of-care diagnostics kits. Various fields, such as infectious disease testing, molecular oncology, and pharmacogenomics, are opening new growth avenues in several MEA countries. Hence, healthcare companies are targeting patients or consumers from several economies. Companies in the healthcare sector have invested significant amounts of their revenue in R&D activities to develop better and advanced offerings and technologies. Several activities in the region propel the demand for metabolomics-related services. Thus, the rising prevalence of cancer and technological advancements in several economies boost the cervical cancer diagnosis test market and provide significant growth opportunities to the players operating in the MEA market.
COVID-19 has severely affected the MEA, especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to have a notable impact on healthcare operations in countries. The pandemic had a significant impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers lead to increased cervical cancer incidence and inflame existing health disproportions. Since the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. Diagnostics services have been disrupted in many countries, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions, including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on the market, limited diagnosis, and decreased access to expert gynecologists, further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis is likely to increase over the next few years.
Based on service provider, the diagnostics and research laboratories segment is expected to be fastest growing during forecast period for MEA region. Diagnostic laboratories and research laboratories are among the primary service providers for Cervical Cancer Diagnostic Testing. It has well-established facilities as per the regulatory requirements. The laboratories use all possible diagnostic products and methods to test the test samples provided by the various sampling methods such as biopsies, blood samples. The sample collected from the patients is analyzed and studied using different instruments, reagents, techniques, and technologies. These samples may be further utilized to study the indications or develop the test processes and technologies. Additional lab services provide hospitals, clinics, at-home care, and others to test their in-house test samples. The increasing prevalence of chronic diseases such as cancer, infectious diseases, outsourcing the diagnostics testing activities by individual researchers is among the factors supporting the segment growth during the forecast period.
The overall MEA cervical cancer diagnostic testing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the MEA cervical cancer diagnostic testing market. The process also serves the purpose of obtaining overview and forecast for the MEA cervical cancer diagnostic testing market with respects to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the MEA cervical cancer diagnostic testing market. Abbott; BD; Cooper Companies, Inc.; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among a few players operating in the MEA cervical cancer diagnostic testing market.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA cervical cancer diagnostic testing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The Middle East & Africa (MEA) cervical cancer diagnostic testing market is expected to grow from US$ 218.90 million in 2021 to US$ 282.38 million by 2028. It is estimated to grow at a CAGR of 3.7% from 2021 to 2028. Healthcare players concentrate on several countries due to the large population suffering from cancer in these countries. Moreover, with rising production costs against their practices, they strive to produce sufficient revenue to entertain their investors. Having a presence in growing countries offers reliable and profitable growth opportunities to the major players to lower their operating costs and expand their geographic reach. Advancements in biotechnology have increased the demand for improved diagnostics based on analytical systems in the healthcare market in several countries; they are also easing the shift toward point-of-care diagnostics kits. Various fields, such as infectious disease testing, molecular oncology, and pharmacogenomics, are opening new growth avenues in several MEA countries. Hence, healthcare companies are targeting patients or consumers from several economies. Companies in the healthcare sector have invested significant amounts of their revenue in R&D activities to develop better and advanced offerings and technologies. Several activities in the region propel the demand for metabolomics-related services. Thus, the rising prevalence of cancer and technological advancements in several economies boost the cervical cancer diagnosis test market and provide significant growth opportunities to the players operating in the MEA market.
COVID-19 has severely affected the MEA, especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to have a notable impact on healthcare operations in countries. The pandemic had a significant impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers lead to increased cervical cancer incidence and inflame existing health disproportions. Since the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. Diagnostics services have been disrupted in many countries, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions, including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on the market, limited diagnosis, and decreased access to expert gynecologists, further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis is likely to increase over the next few years.
Based on service provider, the diagnostics and research laboratories segment is expected to be fastest growing during forecast period for MEA region. Diagnostic laboratories and research laboratories are among the primary service providers for Cervical Cancer Diagnostic Testing. It has well-established facilities as per the regulatory requirements. The laboratories use all possible diagnostic products and methods to test the test samples provided by the various sampling methods such as biopsies, blood samples. The sample collected from the patients is analyzed and studied using different instruments, reagents, techniques, and technologies. These samples may be further utilized to study the indications or develop the test processes and technologies. Additional lab services provide hospitals, clinics, at-home care, and others to test their in-house test samples. The increasing prevalence of chronic diseases such as cancer, infectious diseases, outsourcing the diagnostics testing activities by individual researchers is among the factors supporting the segment growth during the forecast period.
The overall MEA cervical cancer diagnostic testing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the MEA cervical cancer diagnostic testing market. The process also serves the purpose of obtaining overview and forecast for the MEA cervical cancer diagnostic testing market with respects to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the MEA cervical cancer diagnostic testing market. Abbott; BD; Cooper Companies, Inc.; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among a few players operating in the MEA cervical cancer diagnostic testing market.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA cervical cancer diagnostic testing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
127 Pages
- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 MEA Cervical Cancer Diagnostic Testing Market - By Type
- 1.3.2 MEA Cervical Cancer Diagnostic Testing Market - By Service Provider
- 1.3.3 MEA Cervical Cancer Diagnostic Testing Market - By Country
- 2. Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. MEA Cervical Cancer Diagnostic Testing Market - Market Landscape
- 4.1 Overview
- 4.2 MEA PEST Analysis
- 4.3 Experts Opinion
- 5. MEA Cervical Cancer Diagnostic Testing Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Surging Prevalence of Cervical Cancer
- 5.1.2 Escalating HPV Infections
- 5.2 Market Restraints
- 5.2.1 Deficiency of Awareness about the Diagnosis and Treatment Methods
- 5.3 Market Opportunities
- 5.3.1 Development Opportunities in Emerging Countries
- 5.4 Future Trends
- 5.4.1 Rising Development and Launch of Innovative Products
- 5.5 Impact Analysis
- 6. Cervical Cancer Diagnostic Testing Market - MEA Analysis
- 6.1 MEA Cervical Cancer Diagnostic Testing Market Revenue Forecast and Analysis
- 7. MEA Cervical Cancer Diagnostic Testing Market Analysis - By Type
- 7.1 Overview
- 7.2 MEA Cervical Cancer Diagnostic Testing Market, By Type, 2021 & 2028 (%)
- 7.3 PAP Testing
- 7.3.1 Overview
- 7.3.2 PAP Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 7.4 HPV Testing
- 7.4.1 Overview
- 7.4.2 HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 7.5 Colposcopy
- 7.5.1 Overview
- 7.5.2 Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 7.6 Cervical Biopsies
- 7.6.1 Overview
- 7.6.2 Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 7.7 Cystoscopy
- 7.7.1 Overview
- 7.7.2 Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- 8. MEA Cervical Cancer Diagnostic Testing Market Analysis - By Service Provider
- 8.1 Overview
- 8.2 MEA Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)
- 8.3 Diagnostics and Research Laboratories
- 8.3.1 Overview
- 8.3.2 Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
- 8.4 Hospitals and Clinics
- 8.4.1 Overview
- 8.4.2 Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
- 8.5 Specialty Clinics
- 8.5.1 Overview
- 8.5.2 Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
- 8.6 Home Care services
- 8.6.1 Overview
- 8.6.2 Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
- 9. MEA Cervical Cancer Diagnostic Testing Market - Country Analysis
- 9.1 MEA: Cervical Cancer Diagnostic Testing Market
- 9.1.1 Overview
- 9.1.2 MEA: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)
- 9.1.2.1 Saudi Arabia: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.1.1 Saudi Arabia: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.1.2 Saudi Arabia Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- 9.1.2.1.3 Saudi Arabia: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019-2028 (USD Million)
- 9.1.2.2 UAE: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.2.1 UAE: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.2.2 UAE Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- 9.1.2.2.3 UAE: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019-2028 (USD Million)
- 9.1.2.3 South Africa: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.3.1 South Africa: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.3.2 South Africa Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- 9.1.2.3.3 South Africa: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019-2028 (USD Million)
- 9.1.2.4 Rest of MEA: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.4.1 Rest of MEA: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.4.2 Rest of MEA Cervical Cancer Diagnostic Testing Market, by Vaccines Type- Revenue and Forecast to 2028 (USD Million)
- 9.1.2.4.3 Rest of MEA: Cervical Cancer Diagnostic Testing Market, by Service Provider, 2019-2028 (USD Million)
- 10. Impact Of COVID-19 Pandemic on MEA Cervical Cancer Diagnostic Testing Market
- 10.1 MEA: Impact Assessment of COVID-19 Pandemic
- 11. MEA Cervical Cancer Diagnostic Testing Market-Industry Landscape
- 11.1 Overview
- 11.2 Organic Developments
- 11.2.1 Overview
- 11.3 Inorganic Developments
- 11.3.1 Overview
- 12. Company Profiles
- 12.1 F. Hoffmann-La Roche Ltd.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Abbott
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Quest Diagnostics Incorporated
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 QIAGEN
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Hologic, Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Femasys Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Guided Therapeutics, Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Cooper Companies, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 BD
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
- list of Tables
- Table 1. MEA Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (US$ Million)
- Table 2. Saudi Arabia Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- Table 3. Saudi Arabia Veterinary Vaccines Market, by Service Provider - Revenue and Forecast to 2028 (USD Million)
- Table 4. UAE Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- Table 5. UAE Cervical Cancer Diagnostic Testing Market, by Service Provider - Revenue and Forecast to 2028 (USD Million)
- Table 6. South Africa Cervical Cancer Diagnostic Testing Market, by Type- Revenue and Forecast to 2028 (USD Million)
- Table 7. South Africa Cervical Cancer Diagnostic Testing Market, by Service Provider - Revenue and Forecast to 2028 (USD Million)
- Table 8. Rest of MEA Cervical Cancer Diagnostic Testing Market, by Vaccines Type- Revenue and Forecast to 2028 (USD Million)
- Table 9. Rest of MEA Cervical Cancer Diagnostic Testing Market, by Service Provider - Revenue and Forecast to 2028 (USD Million)
- Table 10. Organic Developments
- Table 11. Inorganic Developments
- Table 12. Glossary of Terms
- List of Figures
- Figure 1. MEA Cervical Cancer Diagnostic Testing Market Segmentation
- Figure 2. MEA Cervical Cancer Diagnostic Testing Market, By Country
- Figure 3. MEA Cervical Cancer Diagnostic Testing Market Overview
- Figure 4. PAP Testing Segment Held Largest Share of the Market in 2021
- Figure 5. South Africa is Expected to Show Remarkable Growth During the Forecast Period
- Figure 6. MEA: PEST Analysis
- Figure 7. Experts Opinion
- Figure 8. Impact Analysis of Drivers and Restraints Pertaining to MEA Cervical Cancer Diagnostic Testing Market
- Figure 9. MEA Cervical Cancer Diagnostic Testing Market Forecast to 2028
- Figure 10. MEA Cervical Cancer Diagnostic Testing Market, by Type, 2021 & 2028 (%)
- Figure 11. MEA Pap Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 12. MEA HPV Testing: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 13. MEA Colposcopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 14. MEA Cervical Biopsies: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 15. MEA Cystoscopy: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 16. MEA Others: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 17. MEA Cervical Cancer Diagnostic Testing Market Share by Service Provider - 2021 & 2028 (%)
- Figure 18. MEA Diagnostic Laboratories and Research Laboratories: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 19. MEA Hospitals and Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 20. MEA Specialty Clinics: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 21. MEA Home Care Services: Cervical Cancer Diagnostic Testing Market Revenue and Forecasts To 2028 (US$ Million)
- Figure 22. MEA: Cervical Cancer Diagnostic Testing Market, by Key Country - Revenue (2021) (USD Million)
- Figure 23. MEA: Cervical Cancer Diagnostic Testing Market, by Country, 2021 & 2028 (%)
- Figure 24. Saudi Arabia: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 25. UAE: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 26. South Africa: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 27. Rest of MEA: Cervical Cancer Diagnostic Testing Market - Revenue and Forecast to 2028 (USD Million)
- Figure 28. Impact of COVID-19 Pandemic on Cervical cancer diagnostics testing Market in MEA Countries
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.